Many men who survive prostate cancer face urinary incontinence as a lasting side effect of treatment. However, recent developments have expanded the range of options available to address this issue.
“There is an increasing array of options for treating urinary incontinence,” said Nathaniel Coddington, MD, a functional reconstructive urologist with AdventHealth Medical Group Urology at DTC. “We’re better at helping men regain their quality of life than ever before.”
Dr. Coddington noted that up to 20% of men treated for prostate cancer experience persistent bladder leakage. While most cases involve minor leakage during physical activity, some patients deal with more severe symptoms that can impact daily life.
“They can’t go out and be social, they can’t exercise, and they often struggle with depression and weight gain,” Dr. Coddington said. “That kind of severe case is rare, but it can be devastating.”
Traditionally, severe incontinence was managed using an artificial urinary sphincter—a surgically implanted device requiring manual operation to urinate. While effective, this solution may not suit all patients.
A newer option now available is the ProACT system. This minimally invasive approach uses two small silicone balloons placed near the bladder neck where the prostate once was. The balloons are connected to ports under the skin and can be adjusted by a doctor to control support and reduce leaks.
“ProACT is going to make a lot of men a lot happier,” Dr. Coddington said.
These advances mean that those diagnosed with prostate cancer have more hope for maintaining their quality of life after treatment.
“When you see a urologist to discuss options, be aware there are new developments in this field,” Dr. Coddington said. “Oncologists work to give you quantity of life, and we give quality of life.”
Prostate cancer remains the second-leading cause of cancer death among men, but early detection greatly improves outcomes; according to the CDC, the five-year survival rate for early-detected cases is 99.8%. Screening typically begins with a PSA blood test; improved biomarker testing has made it easier to identify aggressive cancers while reducing unnecessary treatments.
“We’ve come a long way,” said Dr. Coddington. “We’re much better at treating men who need to be treated and not treating those who don’t.”
Screening recommendations vary based on risk: average-risk individuals should start discussions at age 50; those at higher risk (Black men or those with family history) should consider starting at age 45; highest-risk individuals (multiple family members affected early) may begin as early as age 40.
AdventHealth Orlando—founded in 1908 and located in Orlando, Florida—is led by president Terry Shaw and serves as both a pediatric facility and training hospital.
For further information or consultation regarding post-prostate cancer care options, contact AdventHealth Medical Group Urology at DTC.
